Extended Data Fig. 7: AJCC (8th Edition) Stage is associated with GATA6/ CYP3A/KRT17 ‘hybrid’ cell enrichment in chemo-naïve PDAC-HD samples.
From: Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
a) Bar stat plots showing the number of GATA6/KRT17/CYP3A ‘hybrid’ cells observed in different AJCC stages for both chemo-naïve (n = 69) and post-CTX samples (n = 42). As above, a Pearson χ2-test of independence (two-sided) is provided at the top of each plot and P-values from a one sample proportions test (two-sided) are displayed on the top of each bar. Number of observations (n) cells are provided at the bottom of each bar. P-values were not adjusted for multiple testing. b) Bar plot showing the percent tumor content of GATA6/KRT17/CYP3A ‘hybrid’ cells in chemo-naïve samples (n = 69) for each AJCC stage. A LOESS regression line has been added to each bar plot. c) Hematoxylin and Eosin (H&E) stains of representative patient samples showing the histology of the parental tissue and matched PDO. d) Table describing PDAC-HD organoids used in this study. e) Pharmacotyping of PDOs showing heterogeneity of chemotherapy response. PDOs are ranked by increasing Log (IC50) values for the indicated drug treatments and concentrations. f) Line plot showing the heterogeneity of chemotherapy responses for PDOs resistant and susceptible to irinotecan. g) Line plot showing chemotherapy responses for PDAC-HD PDO h20 which was generated from a patient sample that had received mFFX pre-operatively. Numbers in line plots represent the Log (IC50) rank for the indicated treatment.
